Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KT-579 SAD and MAD Study in Healthy Adult Participants
NCT07412288Phase 1Completed
- Sponsor
- Kymera Therapeutics
- Start
- Feb 2026
- Primary completion
- Aug 2026
- Modality
- Bivalent/Multivalent Binders, PROTACs (E3 ligase recruitment)
- Countries
- 1
01
Overview
Phase 1, randomised trial comparing KT-579 with Placebo (2 arms). Primary endpoints: Incidence of adverse events at Day 38 and Incidence of serious adverse events at Day 38. Started Feb 2026; status: completed.
02
Drugs
KT-579
Beyond the preview
Go deeper on NCT07412288.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07412288.